The REPROCELL Blog

Dr David Bunton

Dr David Bunton
CEO, REPROCELL Europe Ltd.

Recent Posts

New publication by Roche on diarrheal toxicity induced by anti-HER2/3 combination therapy includes REPROCELL human fresh tissue data

[fa icon="calendar'] Jun 26, 2018 5:46:01 AM / by Dr David Bunton posted in Human Tissues, Ussing Chambers

[fa icon="comment"] 0 Comments

A publication in Molecular Cancer Therapeutics has shed new light on the mechanisms by which anti-HER2/3 combination therapies can cause diarrhea.

Continue reading [fa icon="long-arrow-right"]

Do animal experiments translate to humans? A report by Elsevier and Bayer uses big data to shed new light on a hotly debated topic

[fa icon="calendar'] May 25, 2018 11:03:43 AM / by Dr David Bunton

[fa icon="comment"] 0 Comments

The use of animals to predict the risk of adverse effects in humans is a long-standing debate within Pharma and also in society at large. Moreover, safety issues leading to clinical attrition remain a problem and a major financial drain on Pharma.

Continue reading [fa icon="long-arrow-right"]